Charles Schwab
DRUG icon

Charles Schwab’s Bright Minds Biosciences DRUG Stock Holding History

Charles Schwab’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
18,032
+2,714
+18% +$213K ﹤0.01% 2938
2026
Q1 		$1.12M Buy
15,318
+2,853
+23% +$230K ﹤0.01% 2871
2025
Q4 		$973K Buy
12,465
+861
+7% +$57.5K ﹤0.01% 2934
2025
Q3 		$704K Hold
11,604
– – ﹤0.01% 3063
2025
Q2 		$303K Buy
+11,604
New +$348K ﹤0.01% 3304

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Charles Schwab's DRUG Position: Q2 2026 in Review

Charles Schwab increased its Bright Minds Biosciences (DRUG) stake by 18% in Q2 2026, buying an estimated $213K and bringing the position to 18,032 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

Charles Schwab first reported a position in DRUG in Q2 2025 and has held it in 5 quarters since. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Charles Schwab held 18,032 shares of Bright Minds Biosciences worth $1.27M as of Q2 2026.
  • Charles Schwab bought 2,714 Bright Minds Biosciences shares in Q2 2026, an estimated $213K.
  • Bright Minds Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2938 holding.
  • Charles Schwab first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.